Bluejay Diagnostics (BJDX) director buys 12,500 shares at $2

Rhea-AI Filing Summary

Bluejay Diagnostics director Donald R. Chase increased his stake by buying shares directly from the company. On March 14, 2026, he purchased 12,500 shares of Bluejay Diagnostics, Inc. common stock in a private placement at $2.00 per share, a total investment of $25,000. After this transaction, he directly owns 12,525 common shares of the company.

Insider Trade Summary

Net Buyer: 12,500 shares ($25,000)

Net Buy 1 txn

Insider CHASE DONALD R

Role null

Bought 12,500 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$2.00	$25K

Holdings After Transaction: Common Stock — 12,525 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 12,500 shares Purchase price: $2.00 per share Transaction value: $25,000 +1 more

4 metrics

Shares purchased 12,500 shares Common Stock bought on March 14, 2026

Purchase price $2.00 per share Private placement price per common share

Transaction value $25,000 12,500 shares x $2.00 per share

Shares owned after 12,525 shares Direct holdings following the transaction

Key Terms

Common Stock, private placement, open-market purchase

3 terms

Common Stock financial

"security title is listed as Common Stock for the transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

private placement financial

"purchased 12,500 shares of the issuer's common stock from the issuer in a private placement"

A private placement is a way for companies to raise money by selling securities directly to a small group of investors instead of through a public offering. This process is often quicker and less regulated, making it similar to offering a special, exclusive investment opportunity to select individuals or institutions. For investors, it can provide access to unique investment options that are not available on public markets.

open-market purchase financial

"transaction_action field describes the transaction as an open-market purchase"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHASE DONALD R

(Last) (First) (Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON MASSACHUSETTS 01720

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		P		12,500(1)	A	$2	12,525	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 14, 2026, Mr. Chase purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.

	/s/ Donald R Chase	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Bluejay Diagnostics (BJDX) director Donald R. Chase do in this Form 4?

Director Donald R. Chase bought additional Bluejay Diagnostics common shares. He acquired 12,500 shares in a private placement transaction, increasing his direct ownership to 12,525 shares, as disclosed in the Form 4 insider trading report.

How many BJDX shares did Donald R. Chase buy and at what price?

He bought 12,500 shares of Bluejay Diagnostics common stock at $2.00 per share. This private placement purchase represents a total investment of $25,000 based on the disclosed transaction terms in the insider filing.

Was Donald R. Chase’s BJDX share purchase open-market or private placement?

Although coded as a purchase, the footnote explains the shares were bought directly from Bluejay Diagnostics in a private placement. The 12,500 shares were acquired from the issuer at a fixed price of $2.00 per share.

How many Bluejay Diagnostics (BJDX) shares does Donald R. Chase own after the transaction?

Following the reported transaction, Donald R. Chase directly owns 12,525 shares of Bluejay Diagnostics common stock. This new balance reflects his previous holdings plus the 12,500 shares acquired in the March 14, 2026 private placement.

What is the total dollar value of Donald R. Chase’s BJDX share purchase?

The disclosed purchase totals $25,000. Chase acquired 12,500 Bluejay Diagnostics common shares at a price of $2.00 per share in the private placement, as shown in the Form 4 and its accompanying footnote.